Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Highly Accessed Research article

Laboratory testing for cytomegalovirus among pregnant women in the United States: a retrospective study using administrative claims data

Jessica Leung1*, Michael J Cannon2, Scott D Grosse2 and Stephanie R Bialek1

Author affiliations

1 National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30333, USA

2 National Center for Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30333, USA

For all author emails, please log on.

Citation and License

BMC Infectious Diseases 2012, 12:334  doi:10.1186/1471-2334-12-334

Published: 3 December 2012

Abstract

Background

Routine cytomegalovirus (CMV) screening during pregnancy is not recommended in the United States and the extent to which it is performed is unknown. Using a medical claims database, we computed rates of CMV-specific testing among pregnant women.

Methods

We used medical claims from the 2009 Truven Health MarketScan® Commercial databases. We computed CMV-specific testing rates using CPT codes.

Results

We identified 77,773 pregnant women, of whom 1,668 (2%) had a claim for CMV-specific testing. CMV-specific testing was significantly associated with older age, Northeast or urban residence, and a diagnostic code for mononucleosis. We identified 44 women with a diagnostic code for mononucleosis, of whom 14% had CMV-specific testing.

Conclusions

Few pregnant women had CMV-specific testing, suggesting that screening for CMV infection during pregnancy is not commonly performed. In the absence of national surveillance for CMV infections during pregnancy, healthcare claims are a potential source for monitoring practices of CMV-specific testing.

Keywords:
CMV; Cytomegalovirus; MarketScan; Pregnant women; Screening; Laboratory testing